Target intelligence / Profile preview

T cell receptor beta joining 2-2 (TRBJ2-2)

Target: TRBJ2-2
Molecular classification: Receptor complex component (T cell receptor complex), Immune gene segment (germline joining region), Protein coding gene

Overview

T cell receptor beta joining 2-2 is a protein-coding gene segment found within the human TCR beta locus[4]. It encodes the J region of the TCR beta chain involved in the crucial antigen recognition process of T lymphocytes. The TRBJ2-2 segment is recombined together with one of several variable (TRBV) and diversity (TRBD) segments to form the V-D-J region of the beta chain, generating a mature TCR with unique specificity for peptide-major histocompatibility complexes (pMHC) displayed by antigen-presenting cells. This process underpins adaptive immunity, allowing T cells to recognize a vast array of antigens. As a genetic segment, TRBJ2-2 itself does not function as a receptor or therapeutic target, but contributes to the diversity and specificity of T cell immune responses through its role in repertoire generation and junctional diversity[4][3][5].

Other names: TCRBJ2S2TRBJ22TRBJ2-2T cell receptor beta joining 2-2

Biological functions

Adaptive immune responseAntigen recognition (as part of the assembled TCR complex)TCR repertoire generation via somatic recombination

Disease associations

Cancer (notably T cell leukemia/lymphoma, where TCR V(D)J usage profiling is diagnostically relevant)Infection (antigen-specific TREC repertoire analysis)Other (autoimmune disease, immune monitoring)

Biomarkers

TRBJ2-2 segment usage studied as a marker of clonal T cell populations in disease (e.g., lymphomas, monitoring T cell diversity)TCR clonality markers (V(D)J segment usage)Immunosequencing panels often include TRBJ2-2 analysis for immune monitoring

Beyond the preview

Go deeper on T cell receptor beta joining 2-2 (TRBJ2-2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor beta joining 2-2 (TRBJ2-2).

Explore the full profile